文献速递泌尿男性生殖肿瘤

前列腺放疗联合辅助雄激素剥夺治疗较新辅助治疗改善无转移生存:个体患者荟萃分析

Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
PubMed 文献 · J Clin Oncol · 2020-12-04

该个体患者荟萃分析纳入两项随机III期试验(Ottawa 0101和RTOG 9413)共1065例局限期前列腺癌患者,比较辅助与新增(新辅助或同期)雄激素剥夺治疗(ADT)联合放疗的测序效应。

要点

  • 辅助ADT较新辅助ADT显著改善15年PFS(36% vs 29%,HR 1.25)。
  • 辅助组生化失败、远处转移及无转移生存均显著优于新辅助组。
  • 两组晚期≥3级胃肠和泌尿毒性无显著差异。

核心结论

  • 局限期前列腺癌放疗联合ADT的测序与长期PFS和MFS显著相关,支持优先采用辅助而非新辅助ADT,且不增加长期毒性。

研究设计与样本

  • 个体患者荟萃分析纳入两项随机III期试验(Ottawa 0101和RTOG 9413),共1065例患者(新辅助组531例,辅助组534例),中位随访14.9年。

临床怎么用

  • 对于接受前列腺根治性放疗的局限期前列腺癌患者,优先考虑辅助ADT而非新辅助ADT。
  • 辅助ADT策略在不增加晚期≥3级胃肠及泌尿毒性的前提下改善长期肿瘤学结局。

局限性

  • 仅纳入两项随机试验,样本量有限(1065例)。
  • 未评估ADT持续时间的影响,仅关注测序。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There remains a lack of clarity regarding the influence of sequencing of androgen deprivation therapy (ADT) and radiotherapy (RT) on outcomes in prostate cancer (PCa). Herein, we evaluate the optimal sequencing of ADT with prostate-directed RT in localized PCa. METHODS: MEDLINE (1966-2018), Embase (1982-2018), ClinicalTrials.gov, and conference proceedings (1990-2018) were searched to identify randomized trials evaluating the sequencing, but not duration, of ADT with RT. Two randomized phase III trials were identified, and individual patient data were obtained: Ottawa 0101 and NRG Oncology's Radiation Therapy Oncology Group 9413. Ottawa 0101 randomly assigned patients to neoadjuvant or concurrent versus concurrent or adjuvant short-term ADT. Radiation Therapy Oncology Group 9413, a 2 × 2 factorial trial, included a random assignment of neoadjuvant or concurrent versus adjuvant short-term ADT. The neoadjuvant or concurrent ADT arms of both trials were combined into the neoadjuvant group, and the arms receiving adjuvant ADT were combined into the adjuvant group. The primary end point of this meta-analysis was progression-free survival (PFS). RESULTS: The median follow-up was 14.9 years. Overall, 1,065 patients were included (531 neoadjuvant and 534 adjuvant). PFS was significantly improved in the adjuvant group (15-year PFS, 29% v 36%, hazard ratio [HR], 1.25 [95% CI, 1.07 to 1.47], P = .01). Biochemical failure (subdistribution HR [sHR], 1.37 [95% CI, 1.12 to 1.68], P = .002), distant metastasis (sHR, 1.40 [95% CI, 1.00 to 1.95], P = .04), and metastasis-free survival (HR, 1.17 [95% CI, 1.00 to 1.37], P = .050) were all significantly improved in the adjuvant group. There were no differences in late grade ≥ 3 gastrointestinal (2% v 3%, P = .33) or genitourinary toxicity (5% v 5%, P = .76) between groups. CONCLUSION: The sequencing of ADT with prostate-directed RT has significant association with long-term PFS and MFS in localized PCa. Our findings favor use of an adjuvant over a neoadjuvant approach, without any increase in long-term toxicity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Spratt DE, Malone S, Roy S, et al. Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. J Clin Oncol. 2020. PMID: 33275486. doi:10.1200/JCO.20.02438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。